The RE-COVER trial: Dabigatran non-inferior to warfarin in treating acute venous thromboembolism [Classics Series]
Image: CC/L. academia 1. The RE-COVER trial demonstrates that treating acute venous thromboembolism with 6 months of dabigatran 150 mg twice ...